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ABSTRACT 
Background: Pregnancy is a challenge to a woman’s cardiovascular system, and extensive 
haemodynamic changes are required for optimal utero-placental circulation and fetal growth. 
The aim of this thesis was firstly to examine different aspects of vascular function in the same 
women longitudinally during normal pregnancy, and secondly to explore whether there is an 
association between maternal cardiovascular function, placental function, and fetal growth. 
Methods and Main Results: Study I and II were prospective cohort studies investigating 
cardiovascular structure and function in 52 healthy women longitudinally at 14, 24 and 34 
weeks gestation, and nine months postpartum. In Study I, brachial and central blood 
pressure, pulse-wave velocity, augmentation index, common carotid artery structure and 
endothelial function in the brachial artery (FMD) and in the forearm skin microcirculation 
was assessed. The study found that brachial and central blood pressure initially decreased and 
then increased. FMD and endothelium dependent microvascular reactivity increased during 
pregnancy. Pulse wave velocity and augmentation index decreased, reaching a nadir in the 
second trimester. In Study II, cardiac function, myocardial mechano-energetic efficiency 
(MEE), and ventricular-arterial coupling (VAC) were measured. Left ventricular (LV) mass 
and cardiac output (CO) increased during pregnancy. LV diastolic function decreased but 
MEE and VAC maintained during pregnancy. There was a positive correlation between first 
and second trimester heart rate, and birth weight centile. Study III was a cross-sectional 
study (n=56) investigating the association between first trimester vascular function and birth 
weight centile. Maternal first trimester vascular reactivity in the brachial artery, and in the 
forearm skin microcirculation, related positively to birth weight centile. Study IV was a 
cross-sectional study (n=53) investigating the association between levels of circulating 
maternal pregnancy-associated plasma protein A (PAPP-A), and first trimester maternal 
vascular function. PAPP-A correlated positively to first trimester maternal skin microvascular 
endothelial function index. 
Conclusions: During normal pregnancy, there were profound structural and functional 
changes throughout the cardiovascular tree. These changes are probably necessary for 
sufficient fetal growth, which is supported by the observed relation between maternal heart 
rate, vascular vasodilator capacity, and fetal growth. Given that first trimester PAPP-A levels 
relate to placental function, our results suggest that placental function can be reflected by first 
trimester endothelium dependent skin microvascular reactivity. 
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1 INTRODUCTION AND RATIONALE 
 
Pregnancy is a challenge to a woman’s cardiovascular system, and extensive haemodynamic 
changes are required for optimal utero-placental circulation and fetal growth. There is 
evidence supporting a role of maternal arterial dysfunction in both preeclamptic pregnancies 
(PE) and fetal growth restriction (FGR), but the pathway leading up to that remains to be 
elucidated1. PE has long been considered a placental disorder, but very recently, this concept 
has been questioned. Instead, it has been suggested that most cases of PE originate from a 
maternal cardiovascular inability to cope with the great demands of the feto-placental unit2.  
Regardless of exactly what triggers PE and FGR, the maternal cardiovascular system in 
pregnancy is of uttermost interest. In order to correctly interpret deviant cardiovascular 
responses in pregnancies, normal vascular adaptation to pregnancy must first be described. 
Some aspects of the vascular tree have been thoroughly studied during pregnancy, but other 
parts remain insufficiently explored. In particular, only a few studies have examined different 
aspects of vascular function in the same women longitudinally during normal pregnancy.  
The rationale for this thesis was firstly that a better knowledge of vascular physiology during 
normal pregnancy is of great importance, secondly that exploring the association between 
maternal vascular function, fetal growth and placental function could lead to a better 
understanding of the relation between maternal cardiovascular function, fetal growth and 
placental function.  This could provide a better opportunity to identify women and/or their 
offspring at risk of complications during pregnancy or in later in life. 
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2 BACKGROUND 
2.1 THE CARDIOVASCULAR SYSTEM 
The cardiovascular tree consists of the heart, large elastic arteries, muscular arteries, 
arterioles, capillaries, venules and the veins. The heart pumps the blood into the pulmonary 
and systemic circulation in a pulsative fashion; systole includes the contraction of the 
ventricles, and diastole the contraction of the atria and the filling of the ventricles. Thus, the 
blood flow oscillates from the heart, generating a pulse wave that moves along the 
circulatory system. The muscular arteries distribute the blood into the periphery and can 
modify this pulse wave propagation through changes in vascular tone. Next, the blood flow 
reaches the microcirculation that consists of arterioles, capillaries and venules. The 
arterioles are the primary site of vascular resistance as they stand for the greatest change in 
blood flow and pressure; once the blood flow reaches the capillaries it is continuous as 
shown in Figure 1. The capillaries are the site for tissue oxygenation, gas exchange and 
nutrition. Pre-capillary sphincters with smooth muscular cells regulate the capillary blood 
flow through relaxation and constriction as a response to local and nervous factors. The 
venous circulation carries the blood back to the heart. 
 
Figure 1. Blood pressure along the circulatory system 
 
Printed with permission from the American Physiological Society 
Utero-placental circulation 
The uterine arteries arise from the internal iliac arteries and provide the major blood supply to 
the uterus. Between the uterine arteries, the vaginal artery, and the ovarian arteries, 
anastomoses are formed and arcuate arteries give rise to large radial arteries that will enter the 
endometrium to form the spiral arteries. During gestation, trophoblasts invade the spiral 
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arteries and replace the vascular smooth muscle and endothelial layer, forming low resistance 
vessels that are almost independent of maternal vasoconstriction3. Through these tubes, 
maternal blood will enter the intervillous space in spurts forming large lacunae where villi 
will bathe, and nutritional exchanges occur. This type of placenta is called haemochorial 
placenta and is unique to humans and higher primates4. At term, approximately 60-100 spiral 
arteries open up into the intravilleous space5. The diameter of the uterine artery is doubled by 
21 week’s gestation, but there is no, or only little, change in the diameter of the internal iliac 
arteries6. During pregnancy, different parts of the systemic and utero-placental circulation 
differ in responsiveness to vasoactive factors with decreasing sensitiveness to most, but not 
all, vasoconstrictors closer to the intervilleous space7.  The anatomy of the blood vessels 
during the menstrual cycle and during pregnancy is shown in Figure 2.  
Figure 2. The anatomy of the blood vessels in the uterus during the menstrual cycle 
(non-pregnant), and during pregnancy (pregnant).  
 
Printed with permission from The American Physiological Society. 
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The widely dilated placental circulation is dependent on a rapid and extensive increase in 
systemic blood flow, maintained through increased cardiac output and intravascular volume.  
2.2 Preeclampsia 
Preeclampsia occurs in 3-5% of pregnancies and is characterized by the new onset of 
hypertension (brachial BP ≥140/90 mmHg) and one of the following criteria: proteinuria, 
end-organ dysfunction, or fetal growth restriction. Thus, proteinuria is no longer considered 
to be mandatory for the diagnosis of PE8. PE is characterized by an imbalance in pro-
angiogenetic and anti-angiogenetic factors and a generalized maternal endothelial 
dysfunction. The origins of the disorder remain unclear, as discussed in the Introduction. 
Women that develop PE are more likely to show a shallow implantation of the placenta and 
decreased spiral artery remodelling9, but the majority of placentas from preeclamptic 
pregnancies are normal10. PE is often divided into early- and late-onset PE  (diagnosed 
before or after 34+0 weeks gestation, respectively). Ninety percent of PE occurs after 34 
weeks gestation. Pregnancies that develop early-onset PE are more likely to have an 
abnormal placental morphology, and there is more effective screening for early-onset PE, 
but further research is needed in order to determine whether early- and late onset PE are 
separate disorders, or merely different severity levels of the same disease11. PE is still one 
of the leading causes of maternal mortality and morbidity worldwide, and the only cure for 
PE is delivery of the baby and the placenta.  
2.2 Cardiovascular investigations and a window of opportunity  
 
Women with a history of PE or fetal growth restriction have an increased risk of 
cardiovascular disease later in life12 13. Vascular ageing starts early, and subclinical 
atherosclerosis predicts cardiovascular events many years before they appear14. Hypertensive 
disorders during pregnancy and cardiovascular disease share many risk factors15, and might 
arise from the same vascular vulnerability existing already before the pregnancy16. Pregnancy 
can therefore be considered a window on future health. 
There are several methods available for discovering early signs of subclinical 
atherosclerosis; those used in Study I-IV, are shown in Table 1.  
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Table 1. Vascular examinations 
Method Measures Association with 
cardiovascular 
events 
References 
FMD (Flow mediated 
dilatation in the 
brachial artery) 
Endothelial function 
in conduit arteries 
Early event in 
atherogenesis 
Predicts 
cardiovascular 
events and 
mortality. 
Celermajer et al 199217,  
Matsuzawa et al 2015 
18 
PWV (Pulse wave 
velocity) 
Aortic and arterial 
stiffness 
Predicts 
cardiovascular 
events and 
mortality 
Ben-Shlomo et al 
201419 
AIx (Augmentation 
index) 
Wave reflection; 
Arterial stiffness and 
endothelial function 
Sensitive in 
younger 
individuals. 
Predicts 
cardiovascular 
events and 
mortality. 
Vlachopoulus et al 
201020  
McEniery et al 200521 
Brachial Blood 
pressure (BP) 
BP in the upper limb Predicts 
cardiovascular 
events and 
mortality 
Rapsomaniki et al 
201422 
Central BP BP at the aortic root Relates closer to 
cardiovascular 
events and death 
than does brachial 
BP 
Roman et al 200723 
Vlachopoulus et al 
201020 
Common carotid 
artery intima media 
thickness (CCA-IMT) 
Arterial structure and 
atherosclerosis 
Predicts 
cardiovascular 
events 
Eigenbrodt et al 200724 
Laser Doppler 
Fluxmetri with 
Iontophoreses  
Skin microvascular 
reactivity and 
endothelial function 
Associated with 
cardiovascular 
risk.  
Currently no 
evidence of 
predictive value. 
I. Jzerman et al 200325 
 
Hellman et al 201526 
 
  7 
2.3 CARDIOVASCULAR FUNCTION IN PREGNANCY 
Many of the methods available for discovering early signs of subclinical atherosclerosis 
have been used on pregnant women. A summary of the main findings on vascular function 
in normal and hypertensive pregnancies is shown in Table 2. 
Table 2 Main findings on vascular function in normal and hypertensive pregnancy 
Method Findings in 
normal 
pregnancies 
References Findings in 
hypertensive 
pregnancies 
References 
FMD (Flow 
mediated 
dilatation in the 
brachial artery) 
Increases in 
normal  
pregnancy, 
decreases near 
term 
Van Balen et al 
201727 
Lower FMD  
among women 
who subsequently 
develop PE 
 
Noori 201028 
Savvidou 200329 
PWV (Pulse wave 
velocity) 
Either no change 
or decrease.  
Increases slightly 
in the third 
trimester. 
Mahendru et al 
201430 
Khalil et al 200931 
Increased PWV 
proceeds 
preeclampsia 
Hausvater et al 
201232 
Foo et al 201733 
AIx (Augmentation 
index) 
Decreases during 
pregnancy with a 
nadir in the 
second trimester. 
Khalil et al 200931 Increased 
augmentation 
index in, and 
before, 
preeclampsia 
 Hausvater et al 
201232 
Foo et al 201733 
Brachial Blood 
pressure (BP) 
Initial reduction, 
followed by an 
increase in the 
third trimester. 
Macdonald-Wallis 
et al 201534 
Grindheim et al 
201235 
Increased BP at 8 
weeks’ gestation 
and no or small 
decrease in mid-
gestation  
Macdonald-Wallis et 
al 201236 
Central BP Decreases more 
than brachial BP 
in the first part of 
gestation. 
Fujime et al 
201237 
Mahendru et al 
201430 
Higher in women 
subsequently 
developing 
preterm PE 
Khalil et al 201438 
Macdonald-Wallis et 
al36 
Common carotid 
artery dimensions 
(CCA-IMT) 
Either no change 
or slightly 
increase in IMT 
near term 
Akhter et al 201339 Thicker intima, a 
thinner media of 
the CCA were 
found in women 
with PE 
Akhter et al 201740 
Laser Doppler 
Fluxmetri with 
Iontophoreses) 
Limited 
knowledge. 
Increased 
microvascular 
reactivity. 
Stewart et al 
200741 
Conflicting results 
on increased or 
decreased 
microvascular 
reactivity 
Agra et al 201742 
Davis et al 200143 
Khan et al 200544 
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2.3.1 Maternal haemodynamics and hormonal changes 
Normal pregnancy is associated with systemic vasodilatation that occurs as early as 3-4 
weeks after conception45. When conception occur, levels of estrogen and progesterone 
increase due to the extended function of the corpus luteum and the increased levels of human 
chorionic gonadotropin (hCG) produced by the trophoblasts. There is a positive correlation 
between estrogen, progesterone and vasodilatation46.  Also, relaxine, a powerful dilator of 
systemic resistance arteries, rises during pregnancy 47. Peripheral vascular resistance 
decreases to a plateau of 35-40% below pre-pregnant values in the second trimester and then 
increases slightly until term. This decrease in peripheral vascular resistance likely triggers the 
renin–angiotensin–aldosterone system so as to retain sodium and increase plasma volume. 
The increase in plasma volume results in a lower haemoglobin level than in the non pregnant 
state. Plasma volume increases to approximately 50% over pre-pregnant values by 32 weeks 
gestation48. Heart rate increases throughout the entire pregnancy and rises to 20-25% above 
pre-pregnant levels30. 
In preeclamptic pregnancies, the decrease in vascular resistance is absent or insufficient, 
plasma volume expansion is inadequate and haemoglobin levels are higher than in normal 
pregnancies. Reduced plasma volume expansion is also associated with fetal growth 
restriction48 49. 
2.3.2 Blood pressure 
In most studies of normal pregnancy, a decrease in both central and brachial blood pressure 
with a mid-trimester drop has been found, followed by a progressive increase until term. 
Diastolic BP (and thus mean arterial pressure) decrease more than systolic BP35 Central blood 
pressure reflects the pressure in the aorta and has been shown to more strongly relate to 
vascular disease and outcome than does brachial blood pressure, especially in young 
individuals 23. Pulse pressure is the difference between systolic and diastolic blood pressure 
and is largely determined by the elasticity of blood vessels. Elevated pulse pressure has been 
reported early in preeclamptic pregnancies50.  
2.3.3 Endothelial function 
Other than being a semipermeable barrier between blood and tissue, the endothelium is also 
involved in regulating haemostasis, inflammation, angiogenesis and blood pressure. Increased 
blood flow and shear stress (the mechanical tension on the endothelial cells) stimulate the 
endothelial cells to produce nitric oxide (NO), which dilates the smooth vascular cells behind 
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the endothelial layer.  As the vessels dilate, blood flow increases and blood pressure 
decreases. This dilatation is called endothelium dependent vasodilatation and can be assessed 
clinically by deliberate changes in blood flow, for example after occlusion of a vessel that is 
causing ischemia (FMD), or by the pharmacological administration of ACh into the blood 
stream. Vasodilatation can also occur without the endothelium being involved through the 
production of NO by other actors such as smooth muscular cells, neurons and macrophages. 
This dilatation is called endothelium independent vasodilatation and can be assessed 
clinically after the administration of NO-donors like glyceryl trinitrate (GTN) or sodium 
nitroprusside (SNP). Traditionally, endothelium dependent vasodilatation is considered to be 
a predictor of cardiovascular events51; however, recently it has been demonstrated that also 
endothelium independent vasodilatation is associated with cardiovascular risk factors52. Thus, 
when investigating vasodilatation it is important to measure both endothelium-dependent as 
well as -independent vasodilatation in order to correctly distinguish between endothelial 
function and vasodilatation derived through other mechanisms. Endothelial function can be 
assessed both in the larger transport vessels, and in the microcirculation17 53. It is well 
established that endothelial function in both conduit arteries and in the microcirculation, are 
independently associated with cardiovascular risk factors17 25 54. However, they represent very 
different aspects of vascular function; where FMD and FMD/GTN reflect endothelial 
function in larger transport vessels55, while skin microvascular reactivity merely reflects 
capillary circulation important for tissue oxygenation and nutrition. There are different 
regulatory mechanisms involved in different vascular beds, and endothelial function in large 
and small arteries can therefore not be considered to reflect the same thing. It has been 
suggested that microvascular dysfunction precedes endothelial dysfunction in larger 
arteries26. 
During normal pregnancy, a general vasodilatation is necessary in order to hold the rapidly 
increasing plasma volume and maintain a stable blood pressure. The mechanism behind this 
is unclear; however, decreased endothelial responsiveness to vasoconstrictors as well as a 
hormone - mediated increased availability of nitric oxide (NO) is probably partly 
accountable56 57. A vascular inability to dilate and endothelial dysfunction during pregnancy 
is associated with hypertensive disorders during pregnancy as shown in Table 2 48 58 59.  
Endothelial function in the large artery bed 
Flow mediated dilatation of the brachial artery (FMD) is widely used to assess endothelium 
dependent conduit vessel dilatation mediated by shear stress stimulus during reactive 
hyperaemia60. Several studies report that FMD and brachial diameter is increased in the 
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second half of normal gestation, and decreased in hypertensive pregnancies 27 28, Table 2. 
Only one small previous study investigated endothelium independent vasodilatation during 
pregnancy and found no differences compared to non-pregnant individuals61. 
Endothelial function in the skin microcirculation 
The microcirculation consists of arterioles, capillaries and venules and is important for tissue 
oxygenation and nutrition. In hypertensive patients, increased resistance due to 
microvascular dysfunction is an important component of high blood pressure26. 
Iontophoreses and Laser Doppler Fluxmetri (LDF) can assess endothelium dependent and 
independent microvascular reactivity53, and is associated with cardiovascular risk25. There is 
limited knowledge concerning microvascular reactivity during normal and complicated 
pregnancy, Table 2. Previous studies have reported increased microvascular reactivity in 
normal pregnancy41. A very recent study reported microvascular dysfunction in women 12 
months after severe PE62. 
 
2.3.4 Arterial stiffness and structure  
Arterial stiffness and augmentation index 
Pulse wave velocity (PWV) is the propagation speed of the pulse wave that moves along the 
aorta and the other large elastic arteries. When these vessels become stiffer, the pulse wave 
moves faster through the system and PWV increases. PWV is also determined by blood 
pressure and is closely related to cardiovascular risk63, Table 1. Also, the reflected pulse wave 
can be quantified through the augmentation index (AIx), and is an independent predictor of 
cardiovascular events since it contains information about the reflective site (arterial resistance 
and endothelial function) 21, Figure 3. There is a consensus that AIx decreases during normal 
pregnancy, reaching a nadir in the second trimester, whereas studies on PWV show 
inconsistent results with either no change or a decrease during normal pregnancy33, Table 2.  
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Figure 3. Augmentation index 
 
 
AP = augmented pressure, i.e the increase in systolic blood pressure due to the 
reflected pulse wave. PP = pulse pressure. Augmentation index (AIx) is calculated as 
AP/PP x100 (%)  
Arterial structure 
Structural elastic arterial changes during pregnancy can be measured by ultrasonography of 
the carotid artery. Common carotid artery intima-media thickness (CCA-IMT) is a marker of 
subclinical vascular disease and is closely related to CVD risk64. A few previous studies 
investigated IMT and CCA diameter during pregnancy and found indices of increased CCA 
diameter and unaltered or slightly increased IMT during normal pregnancy, and increased 
CCA stiffening toward term has also been observed in healthy pregnancies 39 65. In women 
with PE, a significantly thicker mean common carotid artery intima, thinner media, and 
higher I/M ratio than in normal pregnancy have been reported 66, Table 2. 
2.3.5 Uterine artery Doppler measurements 
Blood flow of the uterine artery increases from 50-60 mL/minute in the late first trimester, to 
500-750 mL/minute at term67. During the first half of pregnancy, uterine artery remodels and 
under normal conditions, at 24 weeks gestation, uterine artery Doppler measurement should 
demonstrate a continuous blood flow during diastole. If a high resistance to blood flow is 
present, the pulsatility index (PI), in which the difference between peak systolic velocity and 
end diastolic velocity divided by time-averaged velocity, becomes high.  A high PI in the 
uterine artery in the second trimester means a higher risk of PE and /or FGR 68. Uterine artery 
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resistance has been presumed to reflect placental conditions and is associated with spiral 
remodelling69. However, ophthalmic artery Doppler assessment is as effective as uterine 
artery assessment in predicting FGR and/or PE 70.  Furthermore, uterine artery pulsatility 
index is highly dependent on heart rate71, which raises the question of what uterine artery PI 
really reflects: placental circulation or merely general maternal vascular adaptation to 
pregnancy2 69?  
2.3.6 Cardiac structure and function  
As a result of the rapidly increasing volume, and a fall in total peripheral resistance, normal 
pregnancy is a state of increased preload and a reduced afterload72. Preload is defined by the 
amount of blood that returns to the right atrium, and afterload is the amount of resistance the 
left ventricle has to overcome in order to eject blood. Cardiac output increases up to 40%, 
which is mainly achieved by increased heart rate and by structural changes.  Left atrial size, 
left ventricular relative wall thickness and left ventricular mass increases throughout 
pregnancy, and a recent meta-analysis stated that normal pregnancy is associated with a 
predominantly concentric LV remodelling 73.  
Findings on systolic and diastolic function in normal pregnancy are somewhat divergent74 75, 
and there is evidence of chamber diastolic dysfunction near term in approximately one fifth 
of all normal pregnancies 76.  
In women subsequently developing PE, abnormal LV remodelling and impaired myocardial 
relaxation can be observed. In cases of severe PE, both diastolic and systolic chamber 
dysfunction can be present77-79. 
Myocardial mechano-energetic efficiency 
A way of examining whether the rapid LV remodelling remains beneficial throughout the 
course of pregnancy is to examine myocardial mechano-energetic efficiency (MEE). MEE 
can be measured as the ratio between systolic work and energy consumption, and expresses 
the amount of oxygen consumed by each contraction per second. Thus, a low MEE indicates 
inefficient LV performance with high energy waste, which is associated with increased 
cardiovascular risk in patients with hypertensive LV hypertrophy80. Despite extensive 
research on cardiac function during pregnancy, MEE during normal and complicated 
pregnancy remains to be explored.  
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Ventricular-arterial coupling 
Elastance refers to the change in blood pressure for a given change in blood volume. A high 
elastance is beneficial as it means a greater sensitivity to volume change. The interaction 
between LV function and the arterial system can be assessed as the ratio between arterial 
elastance and LV end-systolic elastance, i.e. ventricular-arterial coupling (VAC)81. The 
greatest efficiency is achieved when elastances are matched, and even in hypertensive 
disorders changes in LV elastance and arterial elastance often occur parallel with a 
maintained VAC 82. There is insufficient knowledge regarding the importance and predictive 
value of VAC during pregnancy. A few studies investigated VAC in normal and complicated 
pregnancy and found either no change or decreased VAC83 84.  
2.4 FETAL GROWTH  
Fetal growth is determined by a variety of genetic, hormonal and environmental factors 85, as 
shown in Figure 4.  
Figure 4 Determinants of fetal growth 
 
When some of these factors prevent the fetus from reaching its growth potential, fetal growth 
restriction, FGR (also called intrauterine growth restriction IUGR), is present.  FGR affects 3-
7% of all pregnancies (depending on the definition), and is a well-known complication of 
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preeclampsia (PE), but does also appear in normotensive pregnancies86. Sometimes FGR 
develops as a result of a deficient placentation, where a shallow trophoblast invasion and 
altered remodelling of the maternal spiral arteries will subsequently cause diminished 
perfusion and hypoxia in the placenta 87. However, in the majority of pregnancies 
complicated by FGR, placental histology is normal10.  
Fetal growth restriction defined 
FGR can be divided into early-onset (diagnosed ≤ 32 weeks gestation, or late-onset 
(diagnosed >32 weeks) FGR, and is associated with hypertensive disorders during 
pregnancy in 70% and 10% of all cases, respectively88. There is no consensus on the 
definition of FGR, but the most used definition is an estimated fetal weight (EFW) < 10th or  
< the 5th centile89. The terms FGR and small for gestational age (SGA) are not 
interchangeably, and SGA only refer to the fact that the estimated fetal weight or the actual 
birth weight is smaller than the reference population, and might or might not be associated 
with growth impairment. In Sweden, FGR during gestation is classified as EFW < 22% 
than estimated mean for gestational age. A birth weight or EFW  < 22% is equal to an EFW 
or birth weight below the 2.3th percentile and to -2 SD 90. Customized birth weight centiles 
have been developed so as to adjust for factors known to have a major impact on fetal 
growth; sex of the neonate, maternal height, weight, ethnicity and gestational age and 
parity91 92. 
Identification of FGR and neonates that are small for gestational age (SGA) is crucial for 
appropriate antenatal and postnatal care. SGA is associated with preterm labour, placental 
abruption, neonatal morbidity and mortality, and long-term adverse effects in adulthood93 94. 
Delivery of an SGA infant is also associated with maternal cardiovascular morbidity or 
mortality in later life95-97. Therefore, prediction is important as it probably improves the 
outcome98. The combination of second trimester uterine artery Doppler and serum markers, 
such as first trimester levels of PAPP-A, can predict FGR to some extent, but does not fulfil 
the criteria for an effective screening tool99. 
2.5 CARDIOVASCULAR FUNCTION AND FETAL GROWTH 
Growing evidence supports the idea of a relation between maternal cardiovascular function, 
and fetal growth. There is a fairly strong evidence that second and third trimester maternal 
blood pressure is inversely correlated with fetal growth100 101. The same relationship is less 
clear, but probably present, already in the first trimester102 103.  
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Lower plasma volumes have been reported in pregnancies complicated by fetal growth 
restriction48. Impaired FMD has been reported in the third trimester, and 6-24 months after, 
pregnancies complicated by fetal growth restriction 104-106. Whether a dysfunctional 
endothelium is present before the pregnancy, or occurs as a response to pregnancy, is 
uncertain. Fetal growth was associated with mid-gestation endothelium dependent 
microvascular reactivity in one previous study107.  
An attenuated AIx in early pregnancy has been reported to be associated with fetal growth 
restriction in women with chronic hypertension108, and another study showed that first 
trimester maternal arterial elastance was associated with birth weight109.  
Pre-pregnancy to second trimester changes in CO, PVR and cardiac index correlated to birth 
weight Z-score in a previous study110, and another study reported that women with FGR had 
altered left ventricular geometry, impaired myocardial relaxation, and higher prevalence of 
diastolic chamber dysfunction, as compared to women with normal gestation111. Both CO and 
heart rate correlated to birth weight in several previous studies71 110 112.  
2.6 PAPP-A  
Pregnancy-associated plasma protein A (PAPP-A) was first discovered in the serum of 
pregnant women in 1974 113, but it was not until the early 1990s when Brambati et al 
described lower levels of PAPP-A in the serum of pregnant women with aneuploid fetuses, 
that the research accelerated114.  Knowledge of the biological effect of PAPP- A was lacking 
until 1999, when it was discovered that PAPP-A is a proteinase that enhances the tissue 
availability of insulin-like growth factor 1 (IGF-1) by cleavage of IGF-binding proteins115. 
PAPP-A is also detectable in low levels in non-pregnant individuals 116, and is synthesized by 
several cell types, including vascular smooth muscle cells and endothelial cells. PAPP-A is 
increased in patients with acute injury or unstable atherosclerotic disease117-119, and although 
PAPP-A seems to be important for normal tissue repair, inhibition of PAPP-A has proved to 
be a potential treatment for a variety of diseases such as atherosclerosis, cancer, fragility and 
nephropathy120.  
PAPP-A during pregnancy 
PAPP-A is produced by the placenta during pregnancy and occurs in increasing amounts in 
maternal serum. The exact mechanisms behind the effects of PAPP-A during pregnancy 
remain unclear; several different functions have been suggested including matrix 
mineralization, microvascular endothelial cell proliferation and angiogenesis119 121 122. Low 
first trimester PAPP-A levels are associated with both chromosomal anomalies and adverse 
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pregnancy outcomes, such as small size for gestational age, preterm labour, preeclampsia, 
and stillbirth 123 124.  PAPP-A is therefore generally considered to reflect placental invasion 
and circulation, a theory that is further strengthened by the fact that low levels of first 
trimester PAPP-A in maternal circulation is associated with reduced number of capillaries 
and smaller capillary diameters in the placenta125 126.  Interestingly, the majority of the 
amount of PAPP-A during pregnancy is distributed in the maternal circulation; it has been 
demonstrated that the concentration of PAPP-A seen in the umbilical cord at term is 1.000-
fold less than in the maternal circulation127. Nevertheless, PAPP-A seems to be crucial for a 
normal fetal growth128.  
PAPP-A is increased in the third trimester in preeclamptic pregnancies, as compared to 
normal pregnancies129 130, and elevated levels of PAPP-A and E-selectin were reported in 
women 10 years after preeclamptic pregnancies 118. Despite this, one previous study could not 
find any association between high first trimester PAPP-A levels and adverse pregnancy 
outcome131. More research is needed in order to understand the complex role of both the 
friend and foe that PAPP-A represents.  
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3 AIMS OF THE THESIS 
  
• To investigate alterations in vascular structure and function, ranging from the aorta to 
the microcirculation, longitudinally during normal pregnancy.  
 
 
• To assess cardiac function, myocardial mechano-energetic efficiency and ventricular-
arterial coupling longitudinally during normal pregnancy. 
 
 
• To explore whether there is an association between cardiac structure and function 
during pregnancy, and fetal growth. 
 
 
• To examine whether there is an association between maternal endothelial function in 
the first trimester, and fetal growth. 
 
• To investigate whether there is an association between levels of circulating maternal 
pregnancy-associated plasma protein A (PAPP-A), supposedly reflecting placental 
function, and first trimester maternal vascular function. 
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4 METHODS 
4.1 STUDY DESIGNS  
Table 3. Overview of study designs and analyses methods 
 Study Design Number of 
Participants  
Analyses 
Methods 
Study I Prospective 
longitudinal 
observational 
study 
52 Linear mixed 
model 
Study II Prospective 
longitudinal 
observational 
study 
52 Linear mixed 
model, Pearson 
correlation 
coefficient 
Study III Cross-sectional 
observational 
study 
56 Linear regression, 
ANOVA, Kruskal-
Wallis test 
Study IV Cross-sectional 
observational 
study 
53 Linear regression, 
Mann-Whitney U 
test, Student`s t-
test 
 
4.2 STUDY POPULATION  
All four studies (Study I-IV) are based on one single cohort of women examined 
longitudinally during and after their first pregnancy. Previously healthy non-smoking women 
were enrolled in our institution during the routinely performed first trimester combined 
ultrasound and biochemical screening (CUB-test) for Down´s syndrome. Since one of our 
primary aims with this project was to investigate whether maternal vascular function was 
associated with fetal growth, we aimed to include both women with normal fetal size and 
smaller fetal size than expected in the first trimester. Further inclusion criteria were singleton 
pregnancy, regular menstrual cycles, reliable data for last menstrual period, and no observed 
malformations of the fetus at inclusion.  
During 2008 to 2012, 60 women were recruited, two were excluded due to malformations of 
the fetus and a few further participants chose to decline some of the examinations due to 
discomfort. Several women chose not to participate in the last examination post partum. 
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Given this, 58 women participated in the first examination, 51 in the second, 49 in the third 
and 31 in the fourth examination.  
 
Flow-chart of study protocol  
 
Cardiovascular investigations included brachial blood pressure, heart rate, central blood 
pressure, carotid-femoral and carotid-radial pulse wave velocity, augmentation index, flow-
mediated vasodilatation in the brachial artery, Laser Doppler fluxmetri in the skin 
microcirculation, ultrasound of the carotid arteries, and echocardiography.  
Blood samples were also collected for current and later analyses. Non pregnant values were 
obtained nine moths post partum.  Fetal growth was sonographically estimated in gestational 
week 11-14, 24 and 32. Uterine artery Doppler indices were measured in the second trimester 
(gestational week 22-24). Data on maternal background characteristics and pregnancy 
outcome (complications, birth weight etc.) were obtained through questionnaires and from 
medical charts. 
Inclusion	at	gesta.onal	week	11-14	
n=60	
First	trimester	
Second	trimester	
Third	trimester	
Nine	months	
a?er	delivery	
Cardiovascular	inves.ga.ons	
n=31	
Cardiovascular	inves.ga.ons	
n=49	
Cardiovascular	inves.ga.ons	
n=51	
Cardiovascular	inves.ga.ons	
n=58	
Uterine	artery	
measurement	
Record	of	
neonatal	outcome	
through	charts	
n=58	
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4.3 CARDIOVASCULAR EXAMINATIONS 
Blood pressure and heart rate 
Study I-IV 
Brachial BP and heart rate was calculated as the mean of three readings obtained 1 minute 
apart with the participant in the supine position, using an oscillometric device (Omron 705IT, 
Omron Healthcare, Kyoto, Japan) on the right arm with an appropriately sized cuff. 
Arterial stiffness, central blood pressure and augmentation index 
Study I and II 
Pulse wave analysis was performed using a SphygmoCor device (AtCor Pty, West Ryde, 
NSW, Australia) according to current recommendations132. Radial artery waveforms were 
obtained by applanation tonometry and calibrated using brachial systolic and diastolic BP; the 
central aortic waveform was calculated by device software using the generalized transfer 
function, and central blood pressure values were derived. The augmentation index was 
calculated through the software and corrected to a heart rate of 75 bpm. Recordings were 
repeated at the level of the common carotid artery (CCA) and the femoral artery, and pulse 
wave velocity (PWV) was calculated from the direct (carotid-to-radial and carotid-to-
femoral) path length. 
Arterial structure 
Study I 
Ultrasonographic examinations of the left and right CCA were performed using a Vivid 7 
Dimension ultrasound device with a 5 or 7 MHz linear transducer (GE Medical System, 
Horten, Norway) and the subjects in the supine position, as described elsewhere133. An ECG 
signal synchronized the image analysis to the end of diastole. The vessels were scanned at the 
level of the bifurcation, and three B-mode images from the longitudinal view, as well as a 
short sequence of real-time images, were recorded on videotape. CCA intima-media 
thickness was measured along a 10 mm-long segment just proximal to the carotid bulb. The 
intima-media thickness was assessed as the mean value of the distance from the leading edge 
of the lumen-intima interface to the leading edge of the media-adventitia interface of far and 
near walls in the right and left carotid arteries. 
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Endothelial function 
Study I, III and IV 
FMD 
Post-ischemic hyperemia induced flow mediated dilatation (FMD) of the forearm vascular 
bed, which is considered to reflect endothelium dependent vasodilatation, was assessed in the 
non-dominant arm, according to current recommendations134. Vasodilatation was induced by 
inflation of a pneumatic tourniquet placed around the forearm to a pressure of 250 mm Hg for 
5 minutes, followed by release. Brachial artery blood flow and diameter was measured 
proximal to the cuff by a Vivid 7 Dimension ultrasound device with a 9-MHz linear 
transducer. The mean values of three measurements of arterial diameter performed at end 
diastole were calculated at rest and at 30, 60, and 90 seconds after cuff release. After a 
washout period of at least 10 minutes to regain stable resting conditions, 0.4 mg glyceryl 
trinitrate given as sublingual spray was used to assess endothelium independent 
vasodilatation. Relative changes in brachial artery diameter after administration of GTN were 
calculated from rest to 4 minutes following drug administration. In order to properly assess 
endothelial functiion we calculated the endothelial function index by the ratio of the 
maximum relative increase in FMD/GTN, as previously proposed135 . In our laboratory, the 
coefficient of variation for FMD is 15%. Local shear rate was calculated as blood 
velocity/brachial artery internal diameter. 
Skin microcirculation 
Endothelium dependent and independent forearm skin microvascular dilatation was assessed 
using laser Doppler perfusion imaging and iontophoretic administration of acetylcholine 
(ACh) and sodium nitroprusside (SNP)136, as shown in Figure 5.  Electrode chambers (LI611 
Drug Delivery Electrode Imaging; Perimed, Järfälla, Sweden) were attached to the volar side 
of the forearm and filled with 0.5 ml of either ACh (2%) or SNP (2%). A battery-powered 
iontophoresis controller (Perilont 382b; Perimed) provided a direct current (0.1 mA for 60 s) 
for drug iontophoresis. Skin microvascular flux (expressed in arbitrary units, AU) before, 
during, and after iontophoresis was recorded (PeriScan PIM II; Perimed) continuously up to 
10 and 14 minutes after iontophoresis of Ach and SNP, respectively, and peak microvascular 
flux was determined. To assess endothelial dependant vasodilatation and also account for 
non-specific vascular reactivity in the skin microcirculation, the ratio ACh/SNP was 
calculated. In our laboratory, coefficients of variation for peak microvascular flux after 
iontophoreses of ACh and SNP are 11% and 20%, respectively.  
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Uterine artery pulsatility index 
Study III 
Uterine artery pulsatility index (PI) was measured abdominally in gestational week 22-24. 
The ultrasound probe was held in the sagittal axis and moved laterally. B-mode ultrasound 
examination with colour Doppler was used to visualize the vessels lateral to the uterus and 
identify the uterine artery at the apparent crossover with the external iliac artery. A pulsed-
wave Doppler gate was then placed over the uterine artery with an angle of insonation of less 
than 60 °. The PI, calculated as the difference between peak systolic velocity and end 
diastolic velocity divided by time-averaged velocity, was measured in both vessels, and the 
mean value was calculated.  
Cardiac structure and function 
Study II 
Transthoracic echocardiography was performed in the left antecubital position with a Vivid 7 
system (General Electric, Horten, Norway) equipped with a phased array 3.5 MHz transducer 
(Doppler frequency 5.0–3.5 MHz). Measurements were performed on a minimum of three 
cardiac beats, from which mean values were calculated. Measurements of LV dimension in 
end-systole (LVDes) and end-diastole (LVDed), and interventricular septum (IVS) and 
Figure 5. Laser Doppler 
Fluxmetry with 
Iontophoresis for 
investigation of skin 
microcirculation. Figure 
shown with permission from 
Perimed AB, Järfälla, 
Sweden.  
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posterior wall thickness (PWT) in diastole were made from M-mode recordings137. LV mass 
was calculated as (0.8 × [1.04 × ([LVDed + IVS + PWT]3 − LVDed3) + 0.6 g]), and divided 
by body height2.7 to obtain LV mass index138. LV volumes were calculated from area tracings 
in four- and two-chamber views using the modified Simpson's rule, and the ejection fraction 
was calculated accordingly139. Longitudinal LV systolic function was also evaluated by the 
mitral annular plane systolic excursion measured by M-mode at four sites (septal, lateral, 
inferior, and anterior part of the mitral annulus) from an apical view140. Left and right atrial 
areas were measured in four-chamber view. The right ventricular (RV) outflow end-diastolic 
dimension was measured in parasternal long axis view. The RV inflow end-diastolic basal 
diameter was measured from the apical four-chamber view141. 
Conventional pulsed wave Doppler echocardiography was used for recordings of mitral 
inflow to evaluate LV diastolic function140. The peaks of early (E) and late (A) mitral flow 
velocities were measured, and the E/A ratio was calculated. The deceleration time from mitral 
E wave and isovolumic relaxation time were measured.  
Doppler tissue imaging echocardiography was performed with pulsed wave Doppler in the 
apical four-chamber view. We measured mitral annular velocities in the septal, lateral, 
inferior, and anterior insertion sites of mitral leaflets. Systolic mitral annular velocity (s) and 
early (e'), and late (a') diastolic velocities were measured off-line. The E/e' mean is expressed 
as the mean of e’ sept and e’ lat; and e'/a' mean ratio was calculated as a mean of the 
velocities in the septal, lateral, inferior, and anterior measurements. The E/e' was used as an 
estimate of LV filling pressure. Doppler tissue imaging was also used in the evaluation of RV 
systolic function by measuring the maximal systolic myocardial velocity of the free wall of 
RV with the sample volume placed at the tricuspid annulus. 
MEE was calculated as the ratio between external work and total energy consumption80. To 
estimate external myocardial work, stroke work (SW) was calculated as systolic BP x 
stroke volume x 0.014. The conversion factor 0.014 transforms mmHg x cm3 into gram-
meters142. Total energy consumption or myocardial oxygen consumption (MVO2) 
measured non-invasively can be approximated by using the formula MVO2 ≈ heart rate x 
systolic BP143. Thus, the ratio between external work and total energy consumption can be 
simplified as MEE = stroke volume/heart rate, where heart rate is divided by 60. MEE is 
strongly related to LV mass80, and thus, to obtain an estimate of MEE per g, MEE was 
divided by LV mass.  
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Indices of ventricular-arterial coupling were calculated as effective arterial elastance (LV 
end-systolic pressure/stroke volume), LV end-systolic elastance (LV end-systolic 
pressure/LV end-systolic volume), ventricular-arterial coupling ratio (effective arterial 
elastance/LV end-systolic elastance), total vascular compliance (stroke volume/[systolic BP – 
diastolic BP]), and total peripheral resistance (mean arterial pressure/cardiac output)144. 
4.3 FETAL SIZE AND NEONATAL OUTCOME 
Study II and III 
Biparietal diameter (BPD) and crown rump length (CRL) was measured at inclusion in 
gestational week 11-14. Δ GA was calculated as gestational age discrepancy, i.e difference in 
observed and expected size of fetus, expressed in days. Gestational age was assessed from 
femur length and biparietal diameter in weeks 16-18 according to the Hadlock formula18. All 
sonographers were certified by, and in accordance with, the guidelines of the Fetal Medicine 
Foundation in London. 
Information on gestational week at delivery, birth weight, gender, and any pregnancy 
complications was obtained from medical charts on the delivery wards. Birth weight centile 
was calculated using a customized centile calculator taking into account the gestational age of 
delivery, maternal booking weight, height, parity, ethnic group and sex of the neonate92.   
4.4 BLOOD SAMPLES 
Study I - IV 
Blood samples were collected at the time of the vascular examinations at gestational week 
11-14 and analysed for fasting glucose, cholesterol, and creatinine by standard procedures. 
Venous blood for PAPP-A measurements was collected in serum separator tubes, allowed to 
clot at room temperature for at least 30 min, centrifuged at 1700-2000 G for 10 min. Serum 
was separated and stored at 2-8°C until analysis on the same or the following day by 
immunoassay (AutoDelfia analyser, PerkinElmer, Waltham, MA, USA). Since PAPP-A 
levels are highly related to gestational age, PAPP-A multiples of median (MoM) were 
calculated as a measure of how individual results deviates from the median according to 
current gestational age. 
4.5 STATISTICS 
The sample size was originally calculated from the initial study design to detect a 15% 
difference in FMD (with 2α 0.05 and β 0.80), between two groups; one group (cases) with 
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fetuses that had a gestational age discrepancy of 7 or more days less as would have been 
expected according to menstrual data, and another group (controls) with no or up to 7 days 
gestational age discrepancy. We estimated that 25 women were needed in each group. 
In all studies mean or median values were analysed depending on whether the data was 
normally distributed (as assessed by Shapiro-Wilks test). In Study I and II, data were 
analysed over time using a linear mixed model with appropriate post-hoc tests for pairwise 
comparisons. Correlations were assessed using Pearson´s correlation coefficient. Multivariate 
analyses with adjustment for covariates were performed using linear regression (Study III 
and IV). In Study III, participants were divided into tertiles according to FMD, GTN and 
ACh values and analysed with ANOVA or Kruskal-Wallis test in order to detect potential 
confounding factors. For the same reason, in Study IV, participants were divided into two 
groups according to PAPP-A levels and analysed with Students t-test or Mann-Whitney U-
test respectively. The null hypothesis was rejected when p <0.05.  
4.6 ETHICAL CONSIDERATIONS 
Ethical permits have been obtained for this project from the Regional Ethics Committee in 
Stockholm, Sweden. All subjects provided written informed consent to participate in the 
study. We have ensured that the participation in this study has been voluntarily. The 
confidentiality of the participants has been respected. Some of the investigations could cause 
discomfort, and all participants were informed regarding this. We did put neither the mother 
nor the fetus in any danger and used only safe methods previously evaluated in pregnant 
women. If needed, we made sure that proper medical care was provided. 
The research was independent, of high quality and performed in well-established research-
labs by trained staff. Since the topic is of great importance and to a great extent still 
unexplored, the time and effort put in by the participants was, by our account, reasonable.  
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5 RESULTS 
5.1 SUBJECT CHARACTERISTICS  
Subject characteristics for the entire cohort at inclusion are shown in Table 4. Neonatal 
outcome is shown in Table 5. 60 women were enrolled; two participants were excluded due 
to lethal malformation of the fetus and several participants choose not to participate in all 
cardiovascular examinations.  
Table 4. Subject characteristics of the entire cohort at inclusion (n=58) 
Characteristic Mean±SD or % Range 
Age (years) 31.8±3.6 24–43 
Height (cm) 167.3±5.5 154–182 
Weight (kg) 65.2+11.7 50–106 
Body mass index (kg/m2) 23.2±3.6 18–35 
Serum creatinine (µmol/L) 51.2±7.3 31–71 
Serum total cholesterol 
(mmol/L) 
4.4±0.8 3.0–7.0 
Serum hs-CRP (mg/L) 4.1±3.3 5–19.6 
Plasma glucose (mmol/L) 4.5±0.2 3.9–5.1 
Systolic blood pressure 
(mmHg) 
107 ± 7 92–129 
Diastolic blood pressure 
(mmHg) 
61 ± 6 48–77 
Δ GA discrepancy at 
inclusion, days 
-4.5±3.8 -13–+3 
Weight gain during 
pregnancy, kg 
12.7±3.8 6–21 
Ethnicity = Caucasian 56/58 = 97%  
  GA, gestational age 
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Table 5. Neonatal outcome for the entire cohort (n=58) 
Characteristic Mean±SD or % Range 
Birth weight (g) 3448±368 2630–4120 
Birth-weight centile 42±26 2–98 
Gestational age at delivery 
(days) 
280±11 237–296 
Gender = girl 33/58 = 57%  
SGA ≤ 10th percentile 8/58 = 14%  
SGA ≤ 5th percentile 2/58 = 3.4%  
Mild preeclampsia 2/58 = 3.4%  
Severe preeclampsia 0/58 = 0%  
Mode of delivery 
Caesarean section 9/58 = 16%  
Vacuum-assisted vaginal 
delivery  
4/58 = 7%  
Vaginal delivery 45/58 = 77%  
SGA, small for gestational age  
Information on pregnancy outcome was extracted from medical charts and is therefore 
complete (n=58). In Study I and II, we wanted to investigate cardiovascular function in 
normal pregnancy and thus, the four participants who developed pregnancy complications, 
i.e. PE or SGA ≤ 5th percentile, were excluded. 
5.2 STUDY 1: VASCULAR STRUCTURE AND FUNCTION IN NORMAL 
PREGNANCY 
5.2.1 Summary of main findings 
Brachial blood pressure (BP) decreased in early pregnancy followed by an increase in the 
third trimester. Central BP decreased more than brachial BP in the first trimester. Heart rate 
increased linearly with each trimester. Carotid-femoral pulse wave velocity (PWV) and 
 28 
augmentation index decreased during pregnancy with a nadir in the second trimester. 
Examinations of endothelial function showed an early and persistent improvement in 
endothelial function of the brachial artery. Also, endothelium dependent microvascular 
reactivity increased during pregnancy. Conduit artery diameters (brachial and common 
carotid artery) increased progressively during pregnancy. Microvascular reactivity increased. 
Changes in vascular structure and function during pregnancy, presented as percentage change 
from a non-pregnant state at 9 months postpartum is presented in Figure 6 
Figure 6 Changes in vascular structure and function during pregnancy, presented as 
percentage change from a non-pregnant state at 9 months postpartum
 
A endothelial function; B arterial structure; C arterial stiffness; D blood pressure and heart 
rate. FMD, flow-mediated vasodilatation; GTN, vasodilatation after glyceryl trinitrate; ACh, 
acetylcholine; CCA, common carotid artery; PWV, pulse wave velocity: AIx, augmentation 
index; MAP, mean arterial pressure 
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5.3 STUDY II: CARDIAC STRUCTURE AND FUNCTION IN NORMAL 
PREGNANCY 
5.3.1 Summary of main findings 
Left atrial diameter increased during normal pregnancy. Left ventricular (LV) wall thickness 
increased during, while LV and right ventricular (RV) dimensions remained essentially 
unchanged. Thus, relative wall thickness, LV mass, and LV mass indexed by height2.7 
increased during pregnancy. The changes in LV wall thickness were largely confined to the 
posterior wall. 
Left ventricular stroke volume and cardiac output increased. Late mitral flow velocity (A 
peak velocity) increased and the E/A ratio decreased with advancing gestation, while 
deceleration time and isovolumic relaxation time remained unchanged. Diastolic myocardial 
fibre tissue Doppler velocity (e’/a´ ratio) decreased during pregnancy and reached a nadir in 
the third trimester.  
Both stroke work and energy consumption increased throughout the course of pregnancy and 
thus, MEE remained unchanged. 
Total peripheral resistance and effective arterial elastance decreased in parallel during the 
course of pregnancy. Thus, ventricular–arterial coupling ratio remained unchanged. 
5.3.2 Cardiac function and offspring birth weight  
Heart rate was associated with birth weight centile in the first (r = 0.41, P = 0.002 and second 
(r = 0.46, P = 0.002), trimesters, Figure 7. Other indices of cardiac function were not related 
to birth weight centile or birth weight. 
Figure 7, Relationship between birth weight centile and (A) first trimester heart rate, 
and (B) second trimester heart rate 
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5.4 STUDY III: FETAL GROWTH AND MATERNAL VASCULAR FUNCTION 
5.4.1 Summary of main findings 
Maternal first trimester vascular reactivity in the brachial artery following ischemia (FMD), 
and sublingual glyceryl trinitrate (GTN), related positively to birth weight centile. Also 
maternal endothelium dependent and independent microvascular reactivity were associated 
with birth weight centile in a similar way. 
5.4.2 Related findings 
The study subjects were divided into tertiles according to the exposure (FMD) in order to 
detect potential confounding factors. There were no differences in age, BMI or blood pressure 
between the groups. Uterine artery pulsatility index was higher in women with the lowest 
FMD, as compared to the other two groups with higher FMD. However, when performing a 
univariate analyses using linear regression, first trimester FMD did not predict uterine artery 
pulsatility index (r = 0.20, P= 0.18), 
A sub-group analysis of women with low (≤ 5%) FMD (n=8) showed that first trimester fetal 
size, as well as birth weight centile, was decreased among women with low FMD as 
compared to women with normal (> 5%) FMD.  
 
5.5 STUDY IV: PAPP-A AND MATERNAL VASCULAR FUNCTION 
5.5.1 Summary of main findings 
PAPP-A correlated positively to first trimester maternal skin microvascular endothelial 
function index (peak ACh/peak SNP), but not to peak ACh nor to peak SNP. PAPP-A was 
also inversely related to maternal first trimester vascular reactivity in the brachial artery 
following ischemia (FMD).  
5.5.2 Related findings 
A comparison of women with low (< median) and high (≥ median) PAPP-A MoM levels 
revealed that women with high PAPP-A levels had higher hs-CRP levels, and a tendency to 
higher cholesterol levels than women with low PAPP-A. There were no differences in BMI, 
fasting p-glucose or blood pressure between the groups.
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 SYSTEMATIC ERROR 
Systematic error occurs when the selection of the study group is incorrect, if the variables are 
incorrectly classified, or if the results lack adjustment for factors that interact with these 
variables. 
6.1.1 Selection bias 
If the study group recruited differs in their exposure-to-outcome distribution from the target 
population, selection bias occurs. Selection bias can also occur in the process of getting study 
participants to remain in the study.  
All four studies (Study I-IV) are based on a cohort of previously healthy, non-smoking 
women examined longitudinally during and after their first pregnancy. Since one of our 
primary aims with this project was to investigate if maternal vascular function was associated 
with fetal growth, we intended to include both women with normal fetal size and smaller fetal 
size than expected in the first trimester. Thus, at the start of this research project, we included 
women in two groups; one group (cases) with fetuses that had a gestational age discrepancy 
of 7 or more days less as would have been expected according to menstrual data, and another 
group (controls) with no or up to 7 days gestational age discrepancy. However, as we 
analysed our data, it became apparent that the data on last menstrual period, and thus 
gestational age discrepancy, was very uncertain and difficult to dichotomize. We recruited 38 
controls and 22 participants with small fetuses (gestational age discrepancy of 7 or more 
days), of which two were excluded due to lethal malformations of the fetus. In the control 
group, gestational age discrepancy varied from -6 to + 3 days, as compared to -7 to -13 days 
in the group with small foetuses. We performed analyses according to our initial hypothesis 
and found no differences in either vascular measurements or neonatal outcome between the 
groups. Two participants developed mild PE, both in the group with normal first trimester 
fetal size. Of the eight participants with offspring growth below the 10th percentile, 3 were 
present in the group with small first trimester fetal size, and 5 in the other. Both offspring 
with a birth weight below the 5th percentile had normal first trimester fetal size. Nevertheless, 
an important issue that comes with this approach must be discussed is how our initial 
inclusion criteria based on cases and controls, could bias the results. Though most cases of 
postponed due dates are attributable to uncertainty in LMP, or to fetal gender145, it may also 
reflect early growth restriction. Small first trimester fetal growth is associated with 
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aneuploidy, higher diastolic BP, higher maternal age, and to preterm delivery, low birth 
weight and SGA, but not with PE102 146. Hence, this inclusion criterion has left us with higher 
maternal age, an overrepresentation of girls among the offspring, and a mean birth weight 
centile that is below the expected. The fact that two participants were excluded due to lethal 
malformations of the fetus is not representative of the general population. On the other hand, 
the other background characteristics presented in Tables 4 and 5 are in accordance with a 
larger population. In Study I, fetal size (i.e gestational age discrepancy) in the first trimester 
was analysed as a continuous variable and found to be different in the group with a 
supposedly dysfunctional endothelium dependent vasodilatation in the brachial artery (FMD) 
as compared to women with normal FMD. Although the results should be interpreted with 
great caution since one of the groups only consisted of 8 women, one cannot ignore the fact 
that small first trimester fetal size nevertheless may be of importance, and that we might have 
found differences between the groups with larger sample sizes. Thus, our initial inclusion 
criteria probably lead us to limitations in external validity, but with a wider range of fetal 
growth pattern, and a better opportunity to explore some of our aims.  
On the other hand, in Study I and II, we wanted to investigate normal cardiovascular 
adaptation to pregnancy. In order to do so we decided to move our focus to pregnancy 
outcomes, and disregard first trimester fetal size. Thus, we only included women with normal 
pregnancy outcomes and excluded those who that came to develop any pregnancy 
complications such as hypertensive disorders and/or fetal growth restriction (≤5th percentile). 
Concerns can be raised as to weather this procedure left us with a group of pregnant women 
with non-representative vascular function and a limited external validity. However, the fact 
that the occurrence of hypertensive disorders and/or fetal growth restriction in our study 
sample was at, or rather below, the expected level, indicates that our study group was still, to 
some extent, representative of the target population. Furthermore, since we only included 
women with normal pregnancy outcomes, it should be justified to consider the vascular 
adaptation to pregnancy normal and beneficial in all included participants. 
Loss to follow-up 
Many women chose not to participate in the last examination post partum; 58 women 
participated in the first examination, 51 in the second, 49 in the third and 31 in the forth. 
However, data on maternal background characteristics and pregnancy outcome 
(complications, birth weight etc.) were obtained through questionnaires, and from medical 
charts, and were complete for all participants.  
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If the participants that do not remain in the study differ in their exposure-to-outcome 
distribution from those who completes all study visits, selection bias could occur. To 
investigate whether that was the case in Study I and II, we performed subgroup analyses of 
women who completed all study visits. Women who completed all study visits showed 
similar baseline characteristics and neonatal outcomes as those who did not complete all 
visits, and participants who completed all study visits revealed no differences in 
cardiovascular structure and/or function, as compared to the results from the entire study 
population. 
Misclassification 
In Study I and II, data representing the non-pregnant state were obtained nine months after 
delivery, and there is substantial epidemiological and research evidence to suggest that 
pregnancy has a significant and protracted postpartum effect on the maternal cardiovascular 
system including blood pressure and PWV, but not on CO or FMD 147. To obtain the most 
accurate results possible, the reference values should be obtained before conception30. 
Furthermore, at the last examination, we did not record menstrual phase, known to impact 
vascular function148. It is possible that this has left us with differential misclassification that 
has affected our results. 
6.1.2 Confounding 
A confounding factor is a variable that influences both the exposure and the outcome, and 
affects the association.  
In Study I and II, variables were measured repeatedly in the same women, and we generally 
present crude data and did not adjust for the characteristics of the participants. In Study I, we 
choose to adjust pulse wave velocity for blood pressure, and augmentation index for blood 
pressure and heart rate, according to previous recommendations33.  
In Study II, we performed a secondary analysis on the impact of body size on cardiac 
structure and function during pregnancy since the range of body weight among our 
participants was large, although representative of a Swedish population. Our results suggest 
that body mass index can affect most indices of cardiac structure and function. However, the 
longitudinal changes appeared to be parallel in women with a body mass index below 25 and 
those with a higher body mass index. Thus, since the primary aim of this study was to 
investigate longitudinal changes, this suggests that the large range of body weight did not bias 
our results. Furthermore, correcting cardiac measurements to weight or body suface area 
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(BSA) during pregnancy is probably not accurate since BSA cannot be considered a good 
proxy for the change in body size during pregnancy149.  
In Study III, outcome (birth weight centile) and exposures (indices of vascular function) 
were defined. A number of confounding factors could hypothetically affect the associations 
studied. To deal with this we used birth weight centiles in order to take into account the major 
determinants of birth weight; gestational age at delivery, maternal booking weight, height, 
parity, ethnicity and sex of the neonate. Furthermore, to explore potential confounding factors 
for the vascular parameters, we grouped participants into tertiles according to different 
exposures, and performed multivariate regression analysis with known potential confounders 
for FMD150. However, it is still possible that the results are affected by residual confounding. 
Also in Study IV, residual confounding could be a major issue since knowledge is limited 
regarding what affects, and what is affected by, PAPP-A151. Our sample size was too small to 
investigate that satisfactorily. Thus, the results of Study IV should be interpreted with great 
caution and be taken primarily as hypothesis generating. 
6.2 RANDOM ERROR 
Random error refers to the unpredictable fluctuations in measurements due to limitations of 
the measurement device. This variability is due to chance and can usually be reduced by 
increasing the sample size. 
6.2.1 Precision 
Cardiovascular examinations and analysis are resource intense, which limited our study group 
size and increases the risk of type II error. All cardiovascular examinations were performed in 
well-established research-labs by a limited number of trained staff. However, all four studies 
could have benefited from a larger study group.  
FMD 
FMD is highly user-dependent, but has nevertheless been proven to have good reproducibility 
and low observer variability. In our laboratory, the coefficient of variation for FMD is 15%. 
However, FMD is sensitive to a variety of factors including probe position, stress, sleeping 
disorders, caffeine consumption, and menstrual phase. It is therefore important to standardize as 
many variables as possible in the study protocol. Our study protocol included 10 minutes of rest 
before the examination, lateral position to avoid caval compression, and no intake of 
caffeinated drinks at least 4 hours prior to the examination.  
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Examination of skin microcirculation 
Assessing skin microvascular reactivity with laser Doppler perfusion imaging following 
iontophoretic administration of vasoactive factors is influenced by a wide range of factors; 
room temperature, stress, intake of caffeine, and body position. Our study protocol included 
the same parameters as for FMD and, importantly, a recorded room temperature of 22-24°C. 
In our laboratory, coefficients of variation for peak microvascular flux after iontophoreses of 
ACh and SNP are 11% and 20%, respectively. 
Examination of carotid arteries 
Examination of the carotid arteries with ultrasound is also highly user-dependent. In our 
laboratory, the coefficient of intra-observer and inter-observer variability were 1% and 8%, 
respectively. CCA-IMT measurements are extremely small and thus, image depth and 
resolution is of great importance. Patient position and translation artefact from pulsatile 
jugular vein can affect the results. In Study I, a Vivid 7 Dimension ultrasound device with 
a 5- or 7- MHz linear transducer was used.  Previous studies indicate that the precision of 
the results could have improved by using high-frequency ultrasound, which allows 
identification of the intima and media separately152. 
Pulse wave velocity, central blood pressure and augmentation index 
Pulse wave velocity was analysed in Study I-III and is gold standard for measuring arterial 
stiffness. There is no consensus on which device is most valid during pregnancy33. It is 
important to measure the path length from the carotid to the femoral artery without taking 
into account the curvature of the pregnant uterus.  
We used the SphygmoCor device to assess PWV, and to derive central blood pressures and 
augmentation index. The SphygmoCor uses radial artery waveforms, brachial blood pressure 
and the generalized transfer function to derive central blood pressure. One problem with this 
technique is that any presence of brachial-to-radial amplification of the pulse wave might lead 
to an underestimation of central blood pressure153.  
Cardiac examinations 
Transthoracic echocardiography was performed as described in the Methods section. In our 
laboratory, the intra-assay coefficient of variation, as calculated on LV mass is 1%. This 
method is user-dependent, and the results are highly influenced by loading conditions. 
Since loading conditions change a great deal during pregnancy, the examination should 
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preferably be completed with measurements of myocardial tissue movement, also called 
strain. In order to do this, we used Doppler tissue imaging echocardiography. This method is 
well validated and provides valuable information in hypertensive pregnancies78. There are 
other methods for evaluating myocardial tissue indices, such as 2D and 3D speckle-tracking 
echocardiography, but whether those methods provide any additional information that could 
be important during pregnancy, remains to be studied.  
Examinations of placental function 
Placental function is difficult to measure. Up until today, no method for evaluating placental 
function in vivo has proved to fulfill the needs for a noninvasive, simple and accurate 
method.  The most widely spread method for assessing placental function in vivo is uterine 
artery Doppler measurements, as discussed above2 69. Other methods available are 3D 
ultrasound, MRI and power Doppler154-156, but whether those methods provide any 
additional information that could be useful during pregnancy, remain to be studied157. In 
Study III, the uterine artery pulsatility index was examined in gestational week 24 by trained 
sonographers. The examination should be performed at rest and in a lateral position. Exercise, 
heart rate and uterine contractions could affect the result.  
In Study IV, PAPP-A was considered a proxy for early placental function, and the accuracy 
of that can be questioned. However, apart from the well-established relationship between low 
levels of PAPP-A and adverse pregnancy outcome, previous studies also show that first 
trimester PAPP-A levels are significantly associated with placental thickness, morphology, 
placental vascularization and 3D placental Doppler indices125 158 159. 
Fetal measurements and customized birth weight centiles 
Gestational age at inclusion was assessed on measurements of the biparietal diameter 
(BPD) if it was < 21mm, and otherwise on crown rump length (CRL)160. Expected date of 
delivery was assessed in gestational week 16-18, according to the current Swedish 
recommendation at that time160. According to the American Congress of Obstetricians and 
Gynecologists (ACOG) gestational age should be assessed before 14 weeks gestation, 
however, although the accuracy of the measurement in the first trimester is only marginally 
better than in the second trimester161. Nevertheless, the error in the estimation of gestational 
age could have had a severe impact on the results in Study III, and additional data based on 
gestational age and birth weight centile calculated from the last menstrual period (LMP) 
would have been of interest. The use of customized birth weight centiles can be questioned, 
since there is no evidence of improved outcome when using them162. However, we 
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considered customized birth weight centiles to be the best available tool for estimating each 
infant’s growth in relation to optimal growth potential.  
Statistics 
One of the major strengths of Study II and IV is the longitudinal design in which the entire 
vascular tree was investigated repeatedly in the same women during and after pregnancy. 
This provides us with a unique opportunity to compare and evaluate the interaction between 
different parts of the cardiovascular system. However, one issue of concern that is associated 
with this design is the multiple testing problem and the risk of type 1 error. One way of 
dealing with that problem is to use a higher threshold for significance levels, but that 
commonly requires larger study groups. One can argue that if several examinations and 
results points in the same direction, these concerns could be set aside, although, our results 
should nevertheless be interpreted with some caution due to this. 
6.3 EXTERNAL VALIDITY 
External validity reflects whether the results of a study can be extrapolated to a larger 
population. 
All cardiovascular exams were performed by a limited number of trained and well-
experienced stuff, and thus, the precision in Study I and II was supposedly satisfactory. 
However, as discussed above, the initial inclusion criteria might have left us with a group of 
pregnant women with non-representative vascular function and limited external validity. 
Nevertheless, the fact that the delivery-related variables reflected a Swedish obstetric context 
could indicate that our results are replicable at least to healthy, pregnant Swedish women.  
The extent to which the findings in Study III and IV can be transferred to a larger group of 
pregnant women is limited. This is because of the small sample size and the very small 
proportion of complicated pregnancies. Hence, the results could and should not be 
extrapolated to complicated pregnancies.  
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7 DISCUSSION 
7.1 STRUCTURAL CHANGES 
The heart and the aorta 
Study II found an increase in LV wall thickness and a subsequent increase in LV mass 
during pregnancy. This is in agreement with other studies showing a 15-25% increase in LV 
wall thickness and an increase up to 50% in LV mass during normal pregnancy73 The 
increase in LV wall thickness during pregnancy in our study occurred in the third trimester 
and was largely confined to the LV posterior wall, while changes in the interventricular 
septum were small. This is in agreement with findings in a recent meta-analysis73. We 
observed LVOT and aortic root diameter to remain unaltered, and there were no changes in 
LV diameters in systole or diastole, or in RV diastolic diameter. Previous studies have 
reported either no change or else an increase in LVOT and aortic root diameter, and a slight 
increase in RVEDD in the third trimester163 164. Thus, our findings extend other 
observations73 to suggest that normal pregnancy is associated with a predominantly 
concentric LV remodelling in response to the increased circulatory demand during 
pregnancy.  
Elastic (conduit) arteries 
In Study I, we observed a progressive increase in the diameter of common carotid arteries 
and brachial artery during pregnancy, more prominent in the brachial artery than in the 
common carotid artery (CCA). CCA- intima media thickness decreased, possibly due to 
distension. A few previous studies investigated IMT and CCA diameter during pregnancy 
and found indices of increased CCA diameter and unaltered IMT during normal pregnancy, 
although, increased CCA stiffening toward term have also been observed in healthy 
pregnancies 39 65.  
 
Microcirculation 
Baseline microvascular reactivity was markedly increased during pregnancy as compared to 
baseline conditions; possible indicating increased vessel size also in the arterioles. 
7.1.1 Structural changes in context 
 
We observed profound structural changes throughout the vascular tree during normal 
pregnancy, reaching from the heart to the microcirculation. Interestingly, although the heart 
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remodels extensively during pregnancy, the LV and RV blood volumes remain unaltered, and 
thus, the extra blood volume necessary for sufficient fetal growth must instead be held more 
peripheral and in the venous system. Our results might imply that the more peripheral a 
vessel, the greater change in vessel diameter. Further studies are needed to evaluate this. 
7.2 FUNCTIONAL CHANGES 
The heart and the aorta 
In the Study II, stroke volume increased progressively throughout the trimesters, whereas 
CO reached a plateau in the second trimester. There is agreement that stroke volume and CO 
increases during normal pregnancy but the time course, magnitude, and maintenance, in 
particular during the last trimester, of these alterations remain unclear74 165 The results from 
our longitudinal study extend to findings from a recently published meta-analysis based on 
mostly small studies, both longitudinal and cross sectional, suggesting a non linear increase in 
CO until the second or early third trimester 166. Taken together, our findings and those by 
others72 167, suggest that CO increases in response to the large reduction in total peripheral 
vascular resistance during early pregnancy, and is probably driven by an increase in heart rate 
and stroke volume, where heart rate may be more important during later pregnancy.  
Cardiac diastolic function and/or dysfunction during normal pregnancy has been a topic of 
great interest during the past few years, since evidence of chamber diastolic dysfunction near 
term has been observed in approximately one fifth of all normal pregnancies 76. Additionally, 
chamber diastolic dysfunction is evident in women subsequently developing preterm PE 153. 
We found a progressive reduction in the E/A ratio during normal pregnancy, indicating 
decreased diastolic function, in agreement with others168 169. The E/A ratio is affected by 
blood pressure and heart rate170, which may be potential confounding factors. However, there 
were directionally similar progressive changes in the e´/a ´ratio, a more sensitive marker of 
diastolic function with less potential confounding by increased preload 171 172. Furthermore, 
the progressive increase in E/e´ during pregnancy and left atrial enlargement, findings of 
increased cardiac filling pressures usually associated with increased LV stiffness and 
decreased diastolic function, indicate a progressive impairment of diastolic function during 
normal pregnancy. These findings, in agreement with others75 169, are probably an effect of 
the pregnancy-induced increase in LV wall thickness. Thus, our results suggest that the 
increase in preload in addition to the concentric LV remodelling leads to higher filling 
pressure and slower relaxation in diastole, not due to fibrosis or stiffness, but merely due to a 
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thicker myocardium. Thus, the impaired diastolic function should not be considered to be 
dysfunctional.  
A typical finding in hypertension-induced cardiac remodelling is disproportionate myocardial 
fibrosis and impaired early diastolic relaxation, which is present before LV hypertrophy 
develops173. In contrast, animal studies suggest that temporary cardiac remodelling associated 
with volume overload and LV hypertrophy during pregnancy is accompanied by upregulation 
of vascular endothelial growth factor and increased myocardial angiogenesis, with no 
increase in cardiac fibrosis174. E-deceleration time and isovolumic relaxation time are 
sensitive echocardiographic indices of early diastolic relaxation, less influenced by heart rate 
than the E/A ratio170, and they are associated with myocardial fibrosis173. Accordingly, we 
observed no changes in E deceleration time or isovolumic relaxation time, providing 
circumstantial evidence to suggest that LV remodelling during normal pregnancy is not 
associated with myocardial fibrosis. 
Another way of examining whether the rapid LV remodelling remains beneficial throughout 
the course of pregnancy is to examine myocardial mechano-energetic efficiency (MEE). 
MEE can be measured as the ratio between systolic work and energy consumption, and 
expresses the amount of oxygen consumed by each contraction per second. Thus, a low MEE 
indicates inefficient LV performance with high energy wasting, which is associated with 
increased cardiovascular risk in patients with hypertensive LV hypertrophy80.  Study II is, to 
the best of our knowledge, the first to examine MEE during normal pregnancy. We 
demonstrate that myocardial MEE remaines unaltered, despite the rapid increase in LV mass, 
heart rate and CO. Thus, the myocardium manages to work efficiently in normal pregnancy, 
also in the third trimester when the demands on cardiac function are accomplished by 
impairment of diastolic function. To assess the interaction between the heart and the large 
arteries, indices of ventricular- arterial coupling (VAC) was also measured, and a maintained 
VAC was observed in all trimesters of normal pregnancy. This can be interpreted as a proof 
of matched LV and arterial elastances, and an optimal cardiac efficiency. There is a lack of 
knowledge regarding the importance and predictive value of both MEE and VAC in 
pregnancy. 
Blood pressure, pulse wave velocity and augmentation index 
In Study II, we found that brachial systolic and diastolic BP decreased somewhat in early 
pregnancy, followed by an increase in the third trimester, in agreement with most studies 
during normal pregnancy34 35. More important, however, central BP decreased more than 
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brachial BP during the first part of pregnancy. Our results confirm and extend previous cross 
sectional studies35 37 and smaller studies with longitudinal measurements up to 17 weeks 
postpartum30, and suggest that central BP is reduced more than brachial BP during early 
pregnancy.  
We found that carotid-femoral PWV, a marker of aortic stiffness175, decreased during 
pregnancy. In normal pregnancy, there is probably a significant reduction in PWV to the 
second trimester, although most studies report that the reduction is BP-dependent33. Thus, 
our findings provide new information in support of reduced aortic stiffness during pregnancy. 
Both central pulse pressure and augmentation index decreased during pregnancy. The relative 
changes in augmentation index were larger than those observed for carotid-femoral PWV. 
This suggests that carotid-femoral PWV and augmentation index, although related, provide 
different information. Indeed, whereas PWV better reflects aortic stiffness, also endothelial 
dysfunction and increased arterial resistance are also determinants of augmentation index, 
which may be a more sensitive early marker of arterial stiffness in younger individuals21. Our 
findings of a reduced augmentation index during pregnancy are in concordance with previous 
cross-sectional 176and longitudinal studies31 37. 
In contrast to carotid-femoral PVW, carotid-radial PWV first decreased until mid-pregnancy 
and then increased until term. This was similar to the observed changes in brachial BP and 
may reflect the increase in peripheral resistance in late pregnancy.  
Endothelial function 
In Study II, we observed an early and persistent improvement in endothelial function in the 
forearm skeletal muscle vasculature. An increased FMD during pregnancy is in agreement 
with previous studies 33. However, it is important to measure indices of both endothelium 
dependent and independent vasodilatation, as an increased FMD could also be due to 
increased non-specific vascular smooth muscle responsiveness52. Vessel diameter is inversely 
related to the vascular responses to post-ischemic hyperemia and GTN17. Despite the larger 
resting brachial artery diameter, FMD was markedly enhanced during pregnancy. This 
inverse relationship to vessel diameter is also a likely reason for the apparent reduced 
response to GTN. In Study III, we demonstrated that impaired maternal endothelial function 
in the first trimester is associated with insufficient fetal growth177. This suggests first 
trimester endothelial function to be of great importance for maternal and fetal health during 
pregnancy and beyond. 
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Microvascular reactivity 
We observed increased microvascular reactivity to ACh during pregnancy, suggesting 
increased endothelium dependent microvascular function. This is consistent with our findings 
in the forearm skeletal muscle vasculature. However, in contrast to the forearm skeletal 
muscle vasculature, the response to SNP suggests that also non-specific vascular reactivity in 
the skin microcirculation is also increased during pregnancy. This is in agreement with 
findings from a longitudinal study41, but very few studies have investigated microvascular 
reactivity during normal pregnancy. Other studies have shown altered endothelium dependent 
microvascular reactivity in pregnancies complicated by hypertensive disorders or intrauterine 
growth restriction, but results are diverging178 179. In hypertensive patients, increased 
resistance due to microvascular dysfunction is an important component on the maintenance 
of high blood pressure26 
7.2.1 Functional changes in context 
We observed early and marked functional changes throughout the vascular tree during normal 
pregnancy, reaching from the heart to the microcirculation. In the first and second trimester, 
most indices of vascular function improved: PWV, blood pressures and AIx decreased, 
endothelial function and microvascular reactivity increased. Cardiac systolic function 
improved with increasing stroke volumes and cardiac output throughout normal pregnancy. 
In the third trimester we observed impaired, but not necessary dysfunctional, LV diastolic 
function as a result of impaired LV relaxation and of increased LV chamber stiffness with 
increased filling pressures. In addition to this, we also found increased carotid-radial PWV 
that might indicate, similar to the third trimester increase in blood pressures, an increased 
peripheral resistance in late pregnancy. MEE and VAC remained unaltered also in the third 
trimester, suggesting that the structural and functional cardiovascular changes observed 
during normal pregnancy (including the third trimester), are mainly effective and beneficial. 
However, the last examination was performed in gestational week 32 and thus, we did not 
assess cardiovascular function during the last weeks of gestation.   
7.3 ASSOCIATION WITH FETAL GROWTH 
In Study III, we found that maternal vascular vasodilator capacity in the first trimester, 
assessed both in the brachial artery (largely representing the skeletal muscle vascular bed) 
and in the skin microcirculation, was positively related to birth weight centile. Both markers 
of endothelium dependent (i.e. FMD and ACh) and endothelium independent (i.e GTN and 
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SNP) vasodilatation correlated positively to birth weight centile. Applying a value of FMD ≤ 
5% to define endothelial dysfunction, we also observed an association between reduced 
maternal endothelium dependent vasodilatation and impaired fetal growth already in the first 
trimester. Furthermore, birth weight centile was very low in this group, which may suggest 
that a FMD value of 5% or below during the first trimester is a risk marker for impaired fetal 
growth. However, these results should be confirmed by others, as there were only 8 women in 
the group with FMD ≤ 5.   
Women delivering SGA-offsprings are at higher risk of future cardiovascular disease97 180. 
Our results might imply that impaired vascular vasodilator and/or reduced endothelial 
function is partly responsible for this association.  
In Study II and III, we observed an independent association between first and second 
trimester heart rate and birth weight centile. Our results confirm one previous study on a 
positive relation between heart rate and birth weight centile 71, and similarly previous studies 
have demonstrated a positive relation between CO and birth weight110 112. This finding is in 
line with the association between a general vasodilator capacity and birth weight centile, 
since the increase in heart rate most likely is a result of sympathetic nerve activation in 
response to vascular dilatation and reduced afterload.  
7.4  ASSOCIATION WITH PLACENTAL FUNCTION 
Uterine artery Doppler  
In Study III, we found that the uterine artery pulsatility index was increased in women with 
the lowest tertile of FMD. However, the relationship was not linear. Nevertheless, our results 
might suggest that reduced vasodilatation in the brachial artery, at least to some extent, 
reflects the circulation in the uteroplacental unit. That is, however, given that uterine artery 
features really reflect placental conditions2. Previous studies found no association between 
FMD and uterine artery pulsatility index in normal pregnancy or before the onset of PE181 59. 
However, in one previous study, women with bilateral uterine artery notch had decreased 
FMD182. 
PAPP-A 
In Study IV, we found a positive correlation between forearm skin microvascular 
endothelium dependent vasodilatation and PAPP-A, whereas FMD (indicative of 
endothelium dependent vasodilatation in the brachial artery) showed an inverse relation. 
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During pregnancy, maternal levels of PAPP-A increase rapidly, and low first trimester PAPP-
A levels are associated with both chromosomal anomalies and adverse pregnancy outcomes, 
such as small size for gestational age, preterm labour, preeclampsia, and stillbirth 123 124.  
PAPP-A is, therefore, generally considered to reflect placental invasion and circulation, a 
theory that is further strengthened by the fact that low levels of first trimester PAPP-A in 
maternal circulation are associated with reduced number of capillaries and smaller capillary 
diameters in the placenta125 126. The reason why some pregnant women have reduced levels of 
PAPP-A and impaired endothelium dependent skin microvascular reactivity in our study is 
unclear, but we do know that healthy individuals with a family history of diabetes have 
functional disturbances in skin microcirculation183 with an impaired endothelium dependent 
microvascular dilatation capacity. Accordingly, previous studies reported reduced PAPP-A 
levels in pregnant women with type-2 diabetes, as compared to healthy controls184 185. 
Furthermore, endothelial function in the skin microcirculation is impaired already in 
apparently healthy people with a family history of diabetes183. Reduced endothelial dependent 
skin microvascular reactivity and low levels of PAPP-A in the first trimester may therefore be 
early important markers of metabolic disturbances, and impaired placental function as a result 
of this. However, whether the observed association between low PAPP-A levels and 
decreased endothelium dependent microvascular reactivity in Study IV, contributes to the 
increased risk of adverse pregnancy outcome, remains to be explored. 
PAPP-A is increased in the third trimester in preeclamptic pregnancies, as compared to 
normal pregnancies129 130, and elevated levels of PAPP-A and E-selectin were reported in 
women 10 years after preeclamptic pregnancies 118. PAPP-A is synthesized by several cell 
types, including vascular smooth muscle cells and endothelial cells, and is also detectable in 
non-pregnant individuals. PAPP-A is increased in patients with acute injury or unstable 
atherosclerotic disease117-119. Despite this, one previous study did not find an association 
between high first trimester PAPP-A levels and adverse pregnancy outcome131. 
Given that first trimester PAPP-A levels relate to placental function, our results suggest that 
placental function can be reflected by first trimester endothelium dependent skin 
microvascular reactivity. We hypothesize that first trimester PAPP-A mainly reflects 
placental microvascular reactivity and that reduced endothelial dependent skin microvascular 
reactivity and low levels of PAPP-A in the first trimester may be early important markers of 
maternal metabolic disturbances and impaired placental function. 
More research is needed to confirm our results and to evaluate the significance of the 
observed (and somewhat conflicting) inverse relation between FMD and PAPP-A.   
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8 CONCLUSIONS 
 
• There are early and marked structural and functional changes of the maternal vascular system 
during normal pregnancy. These hemodynamic changes seem to be dependent on normal 
adaptive endothelial and vascular function.  
• Cardiac output increases rapidly during normal pregnancy as a result of an initial increase in 
heart rate, followed by left atrial enlargement and increased left ventricular wall thickness and 
mass. In the third trimester, these structural and functional cardiac changes are accomplished 
by impairment of diastolic function.  
• Cardiac efficiency and ventricular arterial coupling remain unaltered throughout pregnancy, 
suggesting that the structural and functional cardiovascular changes observed during normal 
pregnancy (including the third trimester), are mainly effective and beneficial.  
• There are positive correlations between maternal first and second trimester heart rate, first 
trimester vascular vasodilator capacity, and fetal growth. These associations are probably 
partly explained by the fact that the increase in heart rate is a result of sympathetic nerve 
activation in response to vascular dilatation and reduced afterload.  
• Forearm skin microvascular endothelium dependent vasodilatation is positively related to 
levels of PAPP-A, whereas FMD (indicative of endothelium dependent vasodilatation in the 
brachial artery) shows an inverse relation. This might suggest that the observed association 
between maternal cardiovascular fucntion and fetal growth, at least to some extent, can be 
explained by the fact that maternal skin microvascular reactivity reflects placental capacity.  
In summary, normal cardiovascular adaptation to pregnancy includes early and profound 
structural and functional changes throughout the cardiovascular tree. There are several 
associations between indices of early maternal cardiovascular adaptation to pregnancy, and 
fetal growth. Some of these associations might be explained by the fact that maternal vascular 
function reflects placental circulation.  
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9 FUTURE PERSPECTIVES 
Despite extensive research in the field on hypertensive disorders during pregnancy, the 
pathogenesis of preeclampsia and fetal growth restriction has not been fully elucidated. 
Useful predictive markers and preventive strategies are yet to be discovered. In particular, the 
role and importance of the microcirculation in pregnancy is poorly understood. Although this 
is believed to be involved in many pregnancy-related complications, further research should 
evaluate the potential benefit of assessing microvascular reactivity in early pregnancy. 
Our findings suggest that endothelial function plays an important role in maternal adaptive 
capacity to pregnancy. Based on our results presented in the current thesis, further research 
ought to explore whether there is a predictive value in maternal heart rate, first trimester 
vascular function in the brachial artery or in the skin microvascular reactivity. If so, studies 
on the potential benefit of low dose aspirin or other pharmacological interventions to women 
with impaired first trimester vascular function or lack of increase in heart rate should be 
carried out. 
Currently, the most controversial debate topic in this research field is the role of the placenta 
in preeclampsia. Over recent decades, the main theory on the cause of preeclampsia has 
focused on an inadequate implantation of the placenta. Recently, focus has shifted towards 
the capability of the maternal cardiovascular system to cope with the great demands of 
pregnancy. Further research should be performed to evaluate shared and disparate factors in 
placental and systemic circulation. In order to answer the chicken-and-egg question of what 
comes first, maternal vascular dysfunction or placental hypoperfusion, women must be 
examined before (and during) pregnancy, and the results should be related to pregnancy 
events, fetal growth and placental function. Available methods for assessing placental 
function in vivo are, however, deficient, and thus, improved and more accurate methods are 
needed.  
Cardiac function in normal and hypertensive pregnancies has been extensively explored, 
although the very recent finding on diastolic dysfunction near term in one fifth of all 
apparently normal pregnancies needs further evaluation. Our findings suggest that MEE 
and/or VAC could be useful measurements to distinguish between normal and pathological 
cardiac alterations in pregnancy. Further studies should be performed to investigate the 
predictive value in estimating MEE and VAC in complicated pregnancies. 
Early signs of endothelial impairment, arterial stiffness, and LV diastolic dysfunction precede 
preeclampsia and fetal growth restriction, but are also present in normal pregnancies. Further 
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studies should evaluate whether any of these parameters could have independent predictive 
values, not only for adverse pregnancy outcome, but also for later cardiovascular events. How 
can we better use the information on future health that each woman’s response to pregnancy 
contains? Although there is a well-established relation between hypertensive pregnancies and 
later cardiovascular diseases, preventive strategies are lacking. Future studies should set out 
to create an effective preventive strategy that reduces this risk. Do pharmacological 
interventions that have been proved to reduce maternal and fetal risk during pregnancy, also 
decrease the risk of cardiovascular events later in life? 
Low birth weight impairs offspring’s endothelial function, and future studies should focus on 
how, and when, we can interfere with the unfavorable relation between intrauterine exposure 
to PE or FGR, and offspring cardiovascular impairment. Can pharmacological interventions 
that reduce maternal and fetal risk during pregnancy, also improve endothelial function and 
cardiovascular health in the offspring? 
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund: När en kvinna blir gravid måste hennes hjärt-kärlsystem öka sin kapacitet rejält 
för att tillgodose det växande barnets behov. Moderkakan bildas när det befruktade växer fast 
i livmodern och det är i moderkakan som allt utbyte mellan mamma och foster sker. I slutet 
av graviditeten flödar en halv liter blod genom moderkakan varje minut. Ca 5% av alla 
gravida kvinnor drabbas av havandeskapsförgiftning som innebär högt blodtryck, en generell 
kärlskada och ofta läckage av proteiner i urinen. Ibland är också fostret tillväxthämmat; det 
växer inte som det ska. Man vet fortfarande inte varför havandeskapsförgiftning uppstår. 
Tidigare trodde man att havandeskapsförgiftning och tillväxthämning hos barnet oftast 
berodde på att moderkakan inte bildades på något bra sätt i början av graviditeten, men på 
senare tid har betydelsen av mammans hjärt-kärlfunktion också lyfts fram. Kan det vara så att 
havandeskapsförgiftning och tillväxthämning hos barnet beror på att mammans hjärt-
kärlsystem inte orkar med att öka sin kapacitet tillräckligt mycket för att tillgodose det 
växande barnets behov? För att kunna svara på den frågan är det viktigt att känna till hur en 
normal kapacitetsökning i mammans hjärta och kärl ser ut.  
Detta forskningsprojekt genomfördes för att ta reda på det, och för att undersöka hur 
mammans hjärt- kärlfunktionen under graviditet påverkar barnets tillväxt. 
 
Metod: Vi undersökte 58 kvinnors hjärt- kärlfunktion i graviditetsvecka 11-14, 24 och 34, 
och sedan nio månader efter förlossningen. Barnets tillväxt mättes med ultraljud och utifrån 
födelsevikten.  
 
Resultat: I Studie I och II visade vi att samtliga delar av mammans kärlträd ökar sin kapacitet 
rejält under normal graviditet: hjärtas muskelmassa ökar, större blodmängder pumpas ut med 
varje slag och hjärtat slår snabbare och snabbare under graviditeten. Aortan blir inte större, 
men däremot mer elastisk, vilket innebär att större blodvolymer kan passera utan att 
blodtrycket stiger. De mindre transportkärlen ökar både i diameter och i sin förmåga att 
anpassa sig till ett ökat blodflöde. De allra minska kärlen i huden uppvisade också ökat 
blodflöde och bättre förmåga att anpassa sig till det förändrade blodflödet.  
I Studie III undersökte vi sambandet mellan mammans kärlfunktion och barnets storlek vid 
födseln och såg att ju bättre både de små och mellanstora blodkärlen kunde anpassa sig till ett 
ökat flöde i graviditetsvecka 11-14, desto bättre växte barnen. Vi fann också att barnets 
tillväxt ökade ju högre vilopuls mamman hade första halvan av graviditeten. 
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I Studie IV ville vi undersöka om fyndet i studie III berodde på att mammans kärlfunktion 
speglar moderkakans funktion, och därför undersökte vi sambandet mellan ett protein som 
bildas av moderkakan, PAPP-A, och mammans kärlfunktion. Vi fann att högre PAPP-A-
nivåer korrelerade med ökad reaktivitet i hudens mikrocirkulation, men att det var precis 
tvärtom i de mellanstora blodkärlen: där var högre PAPP-A-nivåer istället korrelerade med 
lägre reaktivitet.  
 
Slutsatser: Under normala graviditeter sker stora förändringar i hjärtat och kärlträdet hos 
gravida kvinnor. Det finns flera samband mellan hjärt- och kärlfunktionen hos mamman 
under graviditeten, och barnets tillväxt. Det sambandet kan till viss del bero på att 
moderkakans och kärlträdets funktion hänger ihop.   
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